North America Rare Diseases Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy), By Route of Administration, By Therapeutic Area, By Country and Growth Forecast, 2022 – 2028
The North America Rare Diseases Treatment Market would witness market growth of 11.9% CAGR during the forecast period (2022-2028).
The presence of caring regulations by governmental agencies, like the Orphan Drug Act, which encourages product development by granting orphan drug designation to potential drug delivery developed by pharma companies, is expected to accelerate market growth. This initiative promotes research & development in the treatment of rare diseases.
Certain factors responsible for the growth of the rare disease treatment market include increased government assistance, incentives for pharmaceutical companies, raising consciousness among individuals and social groups, physician-to-physician communication to find effective treatment options for rare diseases, a rise in infrastructure for persons suffering from rare diseases, and an increment in research incentives due to the prevalence of non-proliferative diseases.
The increasing prevalence of rare diseases has encouraged key players to develop new and improved treatments, which are expected to propel the market over the future years. In addition, the government is making favourable rules and regulations for increasing the availability of rare disease treatments. Also, people's growing preference for a healthy lifestyle is demanding for the advanced healthcare facilities.
The presence of a large number of leading players, as well as advanced healthcare facilities, are some of the major factors expected to drive market growth in the near future. Besides that, rising reimbursement policies in order to organize treatments for patients who have rare diseases, would create more demand for advanced healthcare solutions. The healthcare initiatives of the United States government seek to contribute to broader U.S. development objectives, foreign policy priorities, as well as national security concerns, while also assisting in the improvement of people's health in low- and middle-income countries.
The US market dominated the North America Rare Diseases Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $65,458.2 million by 2028. The Canada market is experiencing a CAGR of 14.5% during (2022 - 2028). Additionally, The Mexico market is exhibiting a CAGR of 13.5% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments covered in the Report:
By Drug Type
- Biologics
- Biosimilar
- Small Molecule
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Injectable
- Oral
- Others
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
- US
- Canada
- Mexico
- Rest of North America
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Rare Diseases Treatment Market, by Drug Type
- 1.4.2 North America Rare Diseases Treatment Market, by Distribution Channel
- 1.4.3 North America Rare Diseases Treatment Market, by Route of Administration
- 1.4.4 North America Rare Diseases Treatment Market, by Therapeutic Area
- 1.4.5 North America Rare Diseases Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition & Scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Acquisition and Mergers
- 3.2.3 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
- 3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
- Chapter 4. North America Rare Diseases Treatment Market by Drug Type
- 4.1 North America Biologics Market by Country
- 4.2 North America Biosimilar Market by Country
- 4.3 North America Small Molecule Market by Country
- Chapter 5. North America Rare Diseases Treatment Market by Distribution Channel
- 5.1 North America Specialty Pharmacy Market by Country
- 5.2 North America Hospital Pharmacy Market by Country
- 5.3 North America Online Pharmacy Market by Country
- Chapter 6. North America Rare Diseases Treatment Market by Route of Administration
- 6.1 North America Injectable Market by Country
- 6.2 North America Oral Market by Country
- 6.3 North America Others Market by Country
- Chapter 7. North America Rare Diseases Treatment Market by Therapeutic Area
- 7.1 North America Cancer Market by Country
- 7.2 North America Cardiovascular Conditions Market by Country
- 7.3 North America Infectious Diseases Market by Country
- 7.4 North America Musculoskeletal Conditions Market by Country
- 7.5 North America Endocrine Disorders Market by Country
- 7.6 North America Metabolic Disorders Market by Country
- 7.7 North America Hematologic Disorders Market by Country
- 7.8 North America Neurological Conditions Market by Country
- 7.9 North America Others Market by Country
- Chapter 8. North America Rare Diseases Treatment Market by Country
- 8.1 US Rare Diseases Treatment Market
- 8.1.1 US Rare Diseases Treatment Market by Drug Type
- 8.1.2 US Rare Diseases Treatment Market by Distribution Channel
- 8.1.3 US Rare Diseases Treatment Market by Route of Administration
- 8.1.4 US Rare Diseases Treatment Market by Therapeutic Area
- 8.2 Canada Rare Diseases Treatment Market
- 8.2.1 Canada Rare Diseases Treatment Market by Drug Type
- 8.2.2 Canada Rare Diseases Treatment Market by Distribution Channel
- 8.2.3 Canada Rare Diseases Treatment Market by Route of Administration
- 8.2.4 Canada Rare Diseases Treatment Market by Therapeutic Area
- 8.3 Mexico Rare Diseases Treatment Market
- 8.3.1 Mexico Rare Diseases Treatment Market by Drug Type
- 8.3.2 Mexico Rare Diseases Treatment Market by Distribution Channel
- 8.3.3 Mexico Rare Diseases Treatment Market by Route of Administration
- 8.3.4 Mexico Rare Diseases Treatment Market by Therapeutic Area
- 8.4 Rest of North America Rare Diseases Treatment Market
- 8.4.1 Rest of North America Rare Diseases Treatment Market by Drug Type
- 8.4.2 Rest of North America Rare Diseases Treatment Market by Distribution Channel
- 8.4.3 Rest of North America Rare Diseases Treatment Market by Route of Administration
- 8.4.4 Rest of North America Rare Diseases Treatment Market by Therapeutic Area
- Chapter 9. Company Profiles
- 9.1 AbbVie, Inc.
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Regional Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 Recent strategies and developments:
- 9.1.5.1 Partnerships, Collaborations, and Agreements:
- 9.2 F. Hoffmann-La Roche Ltd.
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Segmental and Regional Analysis
- 9.2.4 Research & Development Expense
- 9.2.5 Recent strategies and developments:
- 9.2.5.1 Acquisition and Mergers:
- 9.3 Bayer AG
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Segmental and Regional Analysis
- 9.3.4 Research & Development Expense
- 9.4 Novartis AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 Recent strategies and developments:
- 9.4.5.1 Approval and Trails:
- 9.5 Merck Group
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Segmental and Regional Analysis
- 9.5.4 Research & Development Expense
- 9.5.5 Recent strategies and developments:
- 9.5.5.1 Acquisition and Mergers:
- 9.6 Bristol Myers Squibb Company
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Regional Analysis
- 9.6.4 Research & Development Expenses
- 9.6.5 Recent strategies and developments:
- 9.6.5.1 Acquisition and Mergers:
- 9.7 Pfizer, Inc.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Regional & Segmental Analysis
- 9.7.4 Research & Development Expense
- 9.7.5 Recent strategies and developments:
- 9.7.5.1 Partnerships, Collaborations, and Agreements:
- 9.7.5.2 Acquisitions and Mergers:
- 9.8 AstraZeneca PLC
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Regional Analysis
- 9.8.4 Research & Development Expenses
- 9.8.5 Recent strategies and developments:
- 9.8.5.1 Partnerships, Collaborations, and Agreements:
- 9.8.5.2 Acquisition and Mergers:
- 9.9 Takeda Pharmaceutical Company Limited
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Regional Analysis
- 9.9.4 Research & Development Expense
- 9.9.5 Recent strategies and developments:
- 9.9.5.1 Partnerships, Collaborations, and Agreements:
- 9.9.5.2 Acquisition and Mergers:
- 9.10. PTC Therapeutics, Inc.
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Regional Analysis
- 9.10.4 Research & Development Expenses
- 9.10.5 Recent strategies and developments:
- 9.10.5.1 Partnerships, Collaborations, and Agreements:
- 9.10.5.2 Acquisition and Mergers:
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook